Shares of DIAGENS-B (02526), known as the first listed company focused on medical imaging large models, rose more than 7% in morning trading. At the time of writing, the stock was up 6.84% to HK$250, with a turnover of HK$18.78 million.

The company specializes in foundational technological innovation within the AI medical imaging sector. Its self-developed iMedImage® medical imaging foundation model supports 19 imaging modalities and can be applied to over 90% of clinical imaging scenarios. Based on extensive pre-training data, iMedImage® enables rapid training of specialized diagnostic models for specific diseases, achieving significant industry breakthroughs in areas such as low sample requirements, reduced computational power, and faster training cycles.

Additionally, the company's core product, AI AutoVision®, has been recognized by the National Medical Products Administration as a Class III innovative medical device. It is expected to become the first intelligent chromosome karyotype-assisted diagnosis software approved for market launch in the country.

In the first nine months of 2025, the company reported a surge in revenue of 469.8% year-on-year, reaching RMB 112 million, with a gross profit margin as high as 75.9%. The gross margin for its technology licensing business reached 96.5%.